文献速递骨质疏松与钙磷/甲状旁腺

阿巴洛肽提高日本骨质疏松患者腰椎和髋部骨密度:3期ACTIVE-J研究

Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项在日本开展的随机双盲安慰剂对照3期研究纳入骨折高风险骨质疏松的绝经后女性和男性,每日皮下注射阿巴洛肽80微克或安慰剂78周。阿巴洛肽较安慰剂显著提高腰椎、全髋和股骨颈骨密度,安全性与ACTIVE研究相似。

要点

  • 阿巴洛肽80微克每日皮下注射78周,腰椎骨密度较基线变化12.5%(95%CI 10.3%-14.8%),优于安慰剂(P<.001)。
  • 全髋和股骨颈骨密度分别增加4.3%(95%CI 3.3%-5.3%)和4.3%(95%CI 2.9%-5.6%)。
  • 安慰剂组3名参与者的4个椎体出现新发椎体骨折,阿巴洛肽组无新发椎体骨折。

核心结论

  • 在日本骨折高风险绝经后和男性骨质疏松患者中,阿巴洛肽治疗78周大幅提高腰椎、全髋和股骨颈骨密度,提示日本人群疗效与ACTIVE研究人群相似。

研究设计与样本

  • 随机、双盲、安慰剂对照研究,在日本开展,纳入骨折高风险骨质疏松的绝经后女性和男性,每日皮下注射阿巴洛肽80微克或安慰剂78周(18个月)。

主要发现

  • 阿巴洛肽较安慰剂提高腰椎、全髋和股骨颈骨密度(均值[95%CI])分别为12.5%(10.3%-14.8%;P<.001)、4.3%(3.3%-5.3%)和4.3%(2.9%-5.6%)。
  • 血清I型前胶原N端前肽在6周时快速升至基线以上约140%,随后逐渐下降,78周时仍较基线高约25%。
  • 血清I型胶原羧基端交联端肽在24周时逐渐升至基线以上50%,从60周起逐渐降至安慰剂组水平。
  • 安慰剂组3名参与者的4个椎体出现新发椎体骨折,阿巴洛肽组无新发椎体骨折。
  • 安全性特征与ACTIVE研究相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Abaloparatide reduced fracture risk in postmenopausal women with osteoporosis in the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE). Its effect in Japanese patients remains unexamined. OBJECTIVE: This work aimed to determine the efficacy and safety of abaloparatide in increasing bone mineral density (BMD) in Japanese patients with osteoporosis at high fracture risk. METHODS: This was a randomized, double-blind, placebo-controlled study conducted in Japan. Postmenopausal women and men with osteoporosis with high fracture risk were given daily subcutaneous 80 µg abaloparatide or placebo for 78 weeks (18 months). The primary end point was percentage change in lumbar spine (LS) BMD from baseline at the last visit. Secondary end points included time-course changes in LS, total hip (TH), and femoral neck (FN) BMDs and bone turnover markers, and cumulative number of fractures. RESULTS: Abaloparatide increased LS, TH, and FN BMDs (mean [95% CI]) by 12.5% (10.3%-14.8%; P < .001), 4.3% (3.3%-5.3%), and 4.3% (2.9%-5.6%), respectively, vs placebo. Serum procollagen type I N-terminal propeptide increased rapidly to ~ 140% above baseline at 6 weeks and gradually decreased but was approximately 25% higher than baseline at 78 weeks. Serum carboxy-terminal cross-linking telopeptide of type I collagen gradually increased to 50% above baseline at 24 weeks and decreased gradually to the placebo-group level from 60 weeks. Four vertebrae of 3 participants in the placebo group, but none in the abaloparatide group, developed new vertebral fractures. The safety profile was similar to that in the ACTIVE study. CONCLUSION: In Japanese patients with postmenopausal and male osteoporosis with high fracture risk, abaloparatide for 78 weeks robustly increased LS, TH, and FN BMDs, suggesting a similar efficacy in Japanese patients vs the ACTIVE study population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Matsumoto T, Sone T, Soen S, et al. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. J Clin Endocrinol Metab. 2022. PMID: 35977548. doi:10.1210/clinem/dgac486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。